Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-11-17 Legal Proceedings Report
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
因公司对资金占用提起民事诉讼相关股份被冻结的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding the judicial freezing of shares held by certain shareholders due to civil litigation related to the company's funds. It details the number of shares frozen, the parties involved, the legal basis, and the potential impact on control of the company. It also includes opinions from the sponsoring institution and references to related documents. The content is focused on legal proceedings affecting shareholding and control, not on financial results, management changes, or general regulatory filings. The document is relatively short (3225 characters) and is a specific announcement about legal and shareholding status. This fits the definition of a Legal Proceedings Report (LTR), which covers updates on significant lawsuits and regulatory actions involving the company.
2022-11-17 Chinese
国新证券股份有限公司关于云南生物谷药业股份有限公司申请司法再冻结及轮候冻结股东深圳市金沙江投资有限公司及林艳和所持公司股份的核查意见
Regulatory Filings
2022-11-17 Chinese
2022年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2022 fourth extraordinary shareholders' meeting of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting date, location, attendance, agenda items, voting results, and legal opinions confirming the meeting's compliance with laws and company regulations. The content focuses on the announcement of voting results and meeting resolutions rather than the full meeting materials or presentations. The document length is short (1726 characters), and it is a formal announcement of the shareholders' meeting decisions and voting outcomes. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-11-15 Chinese
关于控股股东、实际控制人及相关责任人收到行政处罚及市场禁入决定书的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from a company regarding administrative penalties and market ban decisions imposed by the China Securities Regulatory Commission (CSRC) Yunnan Bureau on the controlling shareholder, actual controller, and related responsible persons. It details the investigation, findings, penalties, and market ban measures related to information disclosure violations. The document includes legal references, penalty amounts, and the impact on the company. It is not a financial report, earnings release, or management discussion but a regulatory announcement about legal and compliance matters. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is sufficient and contains detailed content about the legal proceedings and penalties, not just a brief announcement or certification, so it is not RNS or RPA.
2022-11-03 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is a public announcement regarding the progress of a share repurchase (buyback) program by the company. It details the repurchase plan, including purpose, method, price limits, quantity, funding source, and progress to date. There are no financial statements or comprehensive financial reports included, only an update on the share buyback activity. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buying back or selling its own shares.
2022-11-01 Chinese
国新证券关于云南生物谷药业股份有限公司的专项现场检查报告
Regulatory Filings
2022-11-01 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.